Akiram Therapeutics to Showcase Promising AKIR001 Data at EANM 2026 Congress
Akiram Therapeutics to Present AKIR001 Data
Akiram Therapeutics, a pioneering clinical-stage biotech firm based in Sweden, is thrilled to announce that it will present preliminary clinical results for its lead therapeutic candidate, 177Lu-AKIR001, at the upcoming EANM 2026 Congress held in Vienna from October 17-21. This prestigious event is a significant gathering for experts and professionals in the field of nuclear medicine.
The selected abstract has been recognized as a Top Rated Oral Presentation, affirming its relevance and potential impact in the medical community. The ongoing Phase I trial investigates the efficacy of AKIR001 in patients suffering from irresectable or metastatic CD44v6-positive solid tumors, a patient group that currently lacks viable treatment alternatives.
Promising Preliminary Results
As of the latest update, the study has treated eight patients without observing any dose-limiting toxicities. Most reported treatment-related adverse events were mild, classified as grade 1-2, underlining a favorable safety profile within the examined dosage range. Notably, four patients received a repeat treatment after their initial dose, suggesting the potential for long-term therapeutic applications of AKIR001.
Advanced imaging techniques validated that 177Lu-AKIR001 showed sustained retention in tumors, while efficiently clearing from blood and normal tissues. Additionally, a correlation was noted between low expressions of CD44v6 and reduced absorbed tumor doses, indicating that immunohistochemistry (IHC) could serve as a valuable tool for patient stratification. This insight opens doors for optimized patient selection ahead of the treatment phase.
Insights from Leadership
Marika Nestor, the CEO of Akiram Therapeutics, expressed enthusiasm about the clinical findings, emphasizing their importance as a milestone for AKIR001. Nestor remarked, "We are encouraged by the safety profile and sustained tumor retention observed so far. It is particularly promising that patients have managed to receive repeat treatments, which will be crucial as we move forward with development."
In addition, another study centered on Akiram's CD44v6 targeting strategy has achieved Top Rated Oral Presentation status at EANM 2026. This preclinical evaluation explores the use of AKIR001 alongside a derived single-chain variable fragment (scFv) antibody for theranostic applications in bladder cancer, extending the breadth of Akiram’s innovative approach to different tumor types and antibody formats.
Presentation Details
Here are the details of the presentations scheduled at the EANM 2026 Congress:
- - Oral Presentation (Top Rated)
Presentation No: OP-172
Date & Time: October 18, 4:20 PM
Location: Hall C
Speaker: Joachim Nilsson
- - Oral Presentation (Top Rated)
Presentation No: OP-599
Date & Time: October 20, 10:05 AM
Location: Hall E2
Speaker: Iris Adriana Maria Lodewijk
Conclusion
As Akiram Therapeutics continues its exploration of innovative cancer treatments, the EANM 2026 Congress serves as an important platform for connecting researchers, clinicians, and industry representatives. The developments surrounding AKIR001 contribute significantly to the ongoing battle against challenging types of solid tumors, offering hope for better-targeted therapies in oncology. For more insight, interested parties can visit EANM's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.